Generate QR code
Open Access
Subscription Access
Association of the GRIN2A gene with tardive dyskinesia in schizophrenia patients
https://doi.org/10.25557/2073-7998.2022.08.31-34
Abstract
Tardive or tardive dyskinesia is a severe motor side effect of antipsychotic drugs characterized by involuntary rapid muscle contractions and athetoid movements of the trunk, limbs, and orofacial muscles. The exact mechanism of tardive dyskinesia is still unknown. Glutamate is the main excitatory amino acid neurotransmitter in the mammalian central nervous system. The GRIN2A gene encodes the GluN2 subunit of the ionotropic glutamate receptor NMDA. The aim of this study was to investigate the association of polymorphic variants of the GRIN2A gene with tardive (tardive) dyskinesia in patients taking antipsychotic drugs. 944 patients with schizophrenia were examined (435 women and 509 men), Tardive dyskinesia was diagnosed in 229 patients. Genotyping of 12 polymorphic variants of the GRIN2A gene was carried out. The results of the associative analysis showed that the polymorphic variant rs8057394 is associated with tardive dyskinesia. rs7206256 of the GRIN2A gene showed an association with the orofacial form of dyskinesia. It was also found that the GG genotype and the G allele rs7192557 of the GRIN2A gene have a protective effect against the development of the limbthoracic type of tardive dyskinesia. Thus, it was possible to confirm the hypothesis about the association of the GRIN2A gene with antipsychotic-induced tardive dyskinesia in patients with schizophrenia.
About the Authors
I. V. Pozhidaev
Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
E. G. Poltavskaya
Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
E. G. Kornetova
Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
A. A. Goncharova
Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
S. A. Ivanova
Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
O. Yu. Fedorenko
Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
References
1. Ivanova S.A., Osmanova D.Z., Freidin M.B. et al. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. World J. Biol. Psychiatry. 2017;18:239-246. doi: 10.1080/15622975.2016.1224926
2. Loonen A.J.M., van Praag H.M. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. J. Clin. Psychopharmacol. 2007; 27: 423-430. doi: 10.1097/jcp.0b013e31814f1105.
3. Loonen A.J.M., Ivanova S.A. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18:15-20. doi: 10.1017/s1092852912000752
4. Brosnan J.T., Brosnan M.E. Glutamate: a truly functional amino acid. Amino Acids. 2013;45:413-418. doi: 10.1007/s00726-012-1280-4
5. Traynelis S.F., Wollmuth L.P., McBain C.J. et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 2010;62:405-496. doi: 10.1124/pr.109.002451
6. Poltavskaya E.G., Fedorenko O.Y., Kornetova E.G. et al. Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms. Life (Basel). 2021;11(10):997. doi: 10.3390/life11100997.
7. Ivanova S.A., Loonen A.J.M., Pechlivanoglou P. et al. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl. Psychiatry 2012; 2: e67. doi: 10.1038/tp.2011.66
8. Ivanova S.A., Loonen A.J.M., Bakker P.R. et al. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. SAGE Open Med. 2016; 4: 2050312116643673. doi: 10.1177/2050312116643673
9. Lim K., Lam M., Zai C. et al. Genome wide study of tardive dyskinesia in schizophrenia. Transl. Psychiatry. 2021;11:351. doi: 10.1038/s41398-021-01471-y
10. Andreasen N.C., Pressler M., Nopoulos P. et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry. 2010;67:255-262. doi: 10.1016/j.biopsych.2009.08.040
11. https://sadimod.nl/AIMS-form-Sadimod, accessed on May 23, 2022.
12. Arning L., Kraus P.H., Valentin S. et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics. 2005;6:25-28. doi: 10.1007/s10048-004-0198-8
Review
For citations:
Pozhidaev I.V., Poltavskaya E.G., Kornetova E.G., Goncharova A.A., Ivanova S.A., Fedorenko O.Yu. Association of the GRIN2A gene with tardive dyskinesia in schizophrenia patients. Medical Genetics. 2022;21(8):31-34. (In Russ.) https://doi.org/10.25557/2073-7998.2022.08.31-34
Views:
413
Email this article 